Standardization and Regulatory Guidelines May Inhibit Science and Reduce the Usefulness of Analyses Based on the Application of Preference-Based Measures for Policy Decisions

Mavranezouli I Brazier JE Rowen D Barkham M . Estimating a preference-based index from the Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM): valuation of CORE-6D. Med Decis Making. 2013;33:381–395.

National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: NICE; June 2008.

Dolan P . Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–108.

van Nooten FE Koolman X Brouwer WB . The influence of subjective life expectancy on health state valuations using a 10 year TTO. Health Econ. 2009;18:549–58.

Stiggelbout AM Kiebert GM Kievit J Leer JW Habbema JD De Haes JC . The “utility” of the time trade-off method in cancer patients: feasibility and proportional Trade-off. J Clin Epidemiol. 1995;48:1207–14.

Lin MR Yu WY Wang SC . Examination of assumptions in using time tradeoff and standard gamble utilities in individuals with spinal cord injury. Arch Phys Med Rehabil. 2012;93:245–52.

Dolan P Roberts J , To what extent can we explain time trade-off values from other information about respondents? Soc Sci Med. 2002;54:919–29.

Garau M Shah KK Mason AR Wang Q Towse A Drummond MF . Using QALYs in cancer: a review of the methodological limitations. Pharmacoeconomics. 2011;29:673–85.

Chapman GB Elstein AS Kuzel TM . Prostate cancer patients’ utilities for health states: how it looks depends on where you stand. Med Decis Making. 1988;18:278–86.

Grann VR Panageas KS Whang W Antman KH Neugut AI . Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA-2 positive patients. J Clin Oncol. 1988;16:979–85.

Grann VR Jacobson JS Sundarajan V Alberta SM Troxel AB Neugut AI . The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations. Cancer J Sci Am. 1999;5:283–92.

Robinson A Dolan P Williams A . Valuing health status using VAS and TTO: what lies behind the numbers? Soc Sci Med. 2011;45:1289–97.

Feeny D , Using patient reported outcome measures to improve health and health care. In: Gray DR Noyes S , eds. Patient Reported Outcomes to Improve Performance, Value and Productivity: Symposium Proceedings, Victoria, December 9, 2010; pp 83–9; published online 16 May 2012. Available from: URL: www.effectiveproductivity.info/resources/category/37-patient-reported-outcomes-measures

Brazier JE Yanag Y Tsuchiya A Rowen DL . A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11:212–25.

Brazier J Tsuchyia A . Preference-based condition-specific measures of health: what happens to cross programme comparability? Health Econ. 2010;19:125–9.

Guyatt GH King DR Feeny DH Stubbing D Goldstein RS . Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. J Clin Epidemiol. 1999;52:187–92.

Wiebe S Guyatt G Weaver B Matijevic S Sidwell C . Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol. 2003;56:52–60.

Fryback DG Dunham NC Palta P . U.S. norms for six generic health-related quality of life indexes from the National Health Measurement Study. Med Care. 2007;45:1162–70.

Luo N Chew L-H Fong K-Y . A comparison of the EuroQol-5D and the Health Utilities Index Mark 3 in patients with rheumatic disease. J Rheumatol. 2003;30:2268–74.

Feeny D Wu L Eng K . Comparing Short Form 6D, standard gamble, and Health Utilities Index Mark 2 and Mark 3 utility scores: results from total hip arthroplasty patients. Qual Life Res. 2004;13:1659–70.

Feeny D Spritzer K Hays RD . Agreement about identifying patients who change over time: cautionary results in cataract and heart failure patients. Med Decis Making. 2012;32:273–86.

Lee H Park E Kim HJ Choi J Kim H . Cost-utility analysis of cochlear implants in Korea using different measures of utility. Acta OtoLaryngol. 2006;126:817–23.

UK Cochlear Implant Study Group. Criteria of candidacy for unilateral cochlear implantation in postlingually deafened adults II: cost-effectiveness analysis. Ear Hear. 2004;25:336–60.

Langfitt JT Vickrey BG McDermott MP . Validity and responsiveness of generic preference-based HRQOL instruments in chronic epilepsy. Qual Life Res. 2006;15:899–914.

Henry D , Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals. Pharmacoeconomics. 1992;1:54–67.

Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for Economic Evaluation of Pharmaceuticals: Canada. 2nd ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment; November 1997.

Gold MR Siegel JE Russell LB Weinstein MC , eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.

Laupacis A . Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? CMAJ. 2002;166:44–7.

Laupacis A , Incorporating economic evaluations into decision-making: the Ontario Experience. Med Care. 2005;43(Suppl.):II-15–9.